Want to see DMAC full AI Analyst Report?
Top Page
Diamedica Therapeutics
(NASDAQ:DMAC)
Select Model
Select Model
Rating:50Neutral
Price Target:
$6.50
▼(-3.56% Downside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance (pre-revenue, sustained losses, and rising cash burn), partially offset by a strong low-debt balance sheet and a positive near-term clinical/regulatory milestone path from the latest earnings call. Technicals are broadly neutral, and valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Low leverage / balance sheet
Very low debt and meaningful equity give Diamedica durable financial flexibility to fund clinical programs without heavy interest burdens. A conservatively levered balance sheet reduces refinancing risk, supports continued R&D investment, and makes the company a more attractive partner for collaborations.
Negative Factors
Rising cash burn / negative FCF
Persistent and increasing negative free cash flow creates a structural financing need. Continued burn at current levels makes the company reliant on external capital or partnerships, elevating dilution risk and potentially constraining the pace or scale of future trials if additional funding is delayed or costly.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet
Very low debt and meaningful equity give Diamedica durable financial flexibility to fund clinical programs without heavy interest burdens. A conservatively levered balance sheet reduces refinancing risk, supports continued R&D investment, and makes the company a more attractive partner for collaborations.
Read all positive factors
Diamedica Therapeutics (DMAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$351.60M
Dividend YieldN/A
Average Volume (3M)233.78K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue GrowthN/A
EPS Growth-3.42%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,925,697
10 Day Avg. Volume180,430
30 Day Avg. Volume233,782
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside92.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Diamedica Therapeutics Business Overview & Revenue Model
Company Description
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein...
How the Company Makes Money
null...
Diamedica Therapeutics Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful clinical progress: completion of the first FGR cohort, a supportive Part 1a preeclampsia data set with statistically significant blood pressure reductions and improved uterine perfusion signals, regulatory advances in Canada and planned expansions, and continued progress toward the ReMEDy2 interim analysis with broad site coverage. Financially, the company maintains a cash runway through 2027 but is experiencing a notable decline in cash and working capital versus year-end and materially higher R&D spend and operating cash burn. Operational and regulatory headwinds include enrollment variability, additional rat studies required for a U.S. IND, and a nonlinear dose-response that constrains higher-dose strategies. Overall, the positive clinical momentum and defined regulatory paths outweigh the financing and operational challenges in the near term.Positive Updates
Completed Enrollment in First Cohort of Phase II Fetal Growth Restriction (FGR) Study
Enrollment completed for cohort 1 (6 participants) at 5 µg/kg in open-label Phase II IST for early onset FGR, enabling expansion of DM199 into a second serious women's health indication with no approved therapies; cohort 2 (10 µg/kg) to begin shortly and cohort 3 dose to be chosen between 1–15 µg/kg based on emerging data.
Negative Updates
Decrease in Cash and Working Capital Since Year-End
Cash and short-term investments declined from $59.9M on Dec 31, 2025 to $43.5M on June 30, 2026, a decrease of approximately 27.4%; working capital fell from $55.5M to $37.7M, a decline of approximately 32.1%.
Read all updates
Q2-2026 Updates
Positive
Negative
Completed Enrollment in First Cohort of Phase II Fetal Growth Restriction (FGR) Study
Enrollment completed for cohort 1 (6 participants) at 5 µg/kg in open-label Phase II IST for early onset FGR, enabling expansion of DM199 into a second serious women's health indication with no approved therapies; cohort 2 (10 µg/kg) to begin shortly and cohort 3 dose to be chosen between 1–15 µg/kg based on emerging data.
Read all positive updates
Company Guidance
Management guided that the company is funded through 2027 with cash, cash equivalents and short‑term investments of $43.5M as of June 30, 2026 (vs. $59.9M at 12/31/25), current liabilities $6.6M and working capital $37.7M, with net cash used in operations of $17.2M for the six months ended June 30, 2026; R&D spending was $8.2M (Q2) and $16.1M (YTD) and G&A was $2.3M (Q2) and $4.8M (YTD). Key clinical milestones and timing include ReMEDy2 having surpassed ~85% of the ~200 patients required to trigger the prespecified interim efficacy analysis (expected Q1 2027 after protocol‑defined 90‑day follow‑up and ~4–6 weeks for analysis), ~70 active sites across the U.S., Canada, U.K. and six European countries, and an interim DSMB review that could reestimate final size (range 300–728 patients or futility). For pregnancy programs, the first open‑label FGR cohort is complete (6 patients at 5 µg/kg) with cohort 2 at 10 µg/kg starting soon and cohort 3 to be chosen between 1–15 µg/kg; the Part 1a preeclampsia extension pooled 15 high‑dose patients showing mean systolic BP ↓29.1 mmHg (from 169.3, p<0.001) and diastolic BP ↓17.0 mmHg (from 103.7, p<0.01) with systolic <160 mmHg over 24 hours. Health Canada has authorized a ~30‑patient, 3‑dose open‑label Phase II early onset preeclampsia study (dosing to start in Q4 in Canada and expansion to the U.K. later this year), dosing plans begin at 5 µg/kg then 10 µg/kg (third dose 1–15 µg/kg), and a rat PK/pharmacology study completing in September (reports in October) is planned to support a U.S. IND.Diamedica Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -37.09M | -32.70M | -24.38M | -19.31M | -13.62M | -13.54M |
| Net Income | -37.54M | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
Balance Sheet | ||||||
| Total Assets | 45.00M | 61.37M | 46.34M | 54.16M | 34.40M | 45.55M |
| Cash, Cash Equivalents and Short-Term Investments | 43.50M | 59.89M | 44.15M | 52.90M | 33.50M | 45.11M |
| Total Debt | 185.00K | 240.00K | 340.00K | 400.00K | 469.00K | 52.00K |
| Total Liabilities | 6.66M | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M |
| Stockholders Equity | 38.34M | 56.11M | 40.72M | 51.06M | 31.83M | 44.02M |
Cash Flow | ||||||
| Free Cash Flow | -31.60M | -29.10M | -22.10M | -18.75M | -11.59M | -12.27M |
| Operating Cash Flow | -31.57M | -29.06M | -22.08M | -18.73M | -11.51M | -12.25M |
| Investing Cash Flow | -12.08M | -2.19M | 8.56M | -18.30M | 11.54M | -20.54M |
| Financing Cash Flow | 44.65M | 43.88M | 11.99M | 36.84M | -6.00K | 30.09M |
Diamedica Therapeutics Technical Analysis
Negative
6.74
Price Trends
6.76
Negative
6.46
Positive
7.19
Negative
Market Momentum
-0.05
Positive
44.05
Neutral
25.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMAC, the sentiment is Negative. The current price of 6.74 is above the 20-day moving average (MA) of 6.63, below the 50-day MA of 6.76, and below the 200-day MA of 7.19, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 25.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DMAC.
Diamedica Therapeutics Risk Analysis
Diamedica Therapeutics disclosed 61 risk factors in its most recent earnings report. Diamedica Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Diamedica Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $385.31M | -22.06 | -5.76% | ― | ― | 93.45% | |
54 Neutral | $961.17M | -4.36 | -106.15% | ― | ― | 10.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $351.60M | -9.06 | -77.68% | ― | ― | -3.42% | |
44 Neutral | $24.81M | -0.64 | -64.17% | ― | -100.00% | 82.57% | |
44 Neutral | $463.10M | -11.45 | -34.82% | ― | ― | 41.21% | |
41 Neutral | $365.69M | -2.78 | -56.60% | ― | -100.00% | -49.28% |
* Healthcare Sector Average
DMAC
Diamedica Therapeutics
6.52
0.52
8.67%
TVRD
Tvardi Therapeutics
1.78
-27.42
-93.90%
CAPR
Capricor Therapeutics
6.80
0.20
3.03%
RCKT
Rocket Pharmaceuticals
3.53
-0.01
-0.28%
BNTC
Benitec Biopharma
12.71
-0.50
-3.79%
ANNX
Annexon Biosciences
5.06
2.91
135.35%
Diamedica Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan
Positive
May 21, 2026
DiaMedica Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on May 20, 2026, where investors re-elected seven incumbent directors to the board and reaffirmed the company’s governance continuity. Shareholders also ratifie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.